Legislation that would give terminally ill people a direct path to get experimental treatments raises questions about how the Food and Drug Administration would safeguard patients.
An antibody-based drug reduces the frequency of migraine headaches, according to data reviewed by the Food and Drug Administration. The agency approved Aimovig, priced at about $6,900 a year.
Celgene Corp. has thwarted rival drugmakers eager to make cheaper versions of medicines for a form of blood cancer. Now administration officials are criticizing practices they say hold generics back.
After criticism that the administration's blueprint for drug prices was vague, the secretary of health and human services zeroed in on actions that he said need only his signature.
Drugs like Valium, Xanax and Ativan are more popular than ever. Frequently used to treat anxiety, the medicines can be risky, especially when mixed with alcohol or opioids.
Legal analysts say the decision to overturn Maryland's law could slow momentum for other states that are attempting to take action to curb high drug costs.
Even big clinical studies can miss important drug side effects. Researchers, doctors and drugmakers are looking at patients' experiences posted on social media for clues on problems that were missed.
The Department of Justice and 45 states allege that generic drug makers colluded to divvy up customers and set prices. Prosecutors are now looking at potential involvement by drug distributors.
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn't worked to bring costs down.
When it comes to antidepressants and other psychotropic drugs, author Lauren Slater says,"We don't really know what we're taking into our bodies." Her new book is Blue Dreams.
The Trump administration rolled out a list of actions in its budget proposal to attack drug prices, but most of the measures dance around the edges of the problem.
Alex Azar spent five years in charge of Eli Lilly & Co.'s U.S. operations. During his tenure, the prices for the company's insulin products more than doubled.
Treatment for hepatitis C has improved dramatically in the last decade — so much so that it drew one doctor out of retirement to help make sure more low-income patients are cured.
The Pharmaceutical Research and Manufacturers of America, the brand-name drug industry's main trade group, spent liberally to shift the conversation on prices during the last presidential campaign.
The Republican tax plan could reduce or eliminate federal tax credits that reward companies for developing drugs to treat rare diseases. People who benefit from the medicines have objected.
Drug companies and medical device makers in Puerto Rico are still struggling with power and staffing shortages. One device manufacturer says the future of his industry on the island is uncertain.
For more than three decades, pharmaceutical companies have claimed a 50 percent tax credit for the cost of clinical trials of drugs for rare diseases. The credit is now in jeopardy.
Senators cited ProPublica reporting that found drug companies have been making patients pay for oversize eyedrops and more liquid cancer medications than they need.
When eyedrops dribble down your face, it's not your fault. Drugmakers have long known that their drops of medicine exceed the capacity of the human eye. Why didn't companies make the drops smaller?
A bill passed by the California Legislature requires drugmakers to give 60 days' notice before raising a drug's price by 16 percent or more over two years, and to justify the price increase.
Mavyret, recently approved by the Food And Drug Administration, can cure hepatitis C in eight weeks, at a cost of $26,400. Though still expensive, that's well below the price of other options.
Industry says it costs about $2.7 billion to bring a cancer drug to market. But oncologists who ran the numbers put the average closer to $650 million. Drugs are priced way too high, the doctors say.
